Identification of causal genomic alterations is an indispensable step in the implementation of personalized cancer medicine. Analytical methods play a central role in identifying such changes because of the vast amount of data produced by next generation sequencer. Most analytical techniques are designed for the Illumina platform and are therefore suboptimal for analyzing datasets generated by whole exome sequencing (WES) using the Ion Proton System. Accurate identification of somatic mutations requires the characterization of platform-dependent error profiles and genomic properties that affect the accuracy of sequence data as well as platform-oriented optimization of the pipeline. Therefore, we used the Ion Proton System to perform WES of DNAs isolated from tumor and matched control tissues of 1,058 patients with cancer who were treated at the Shizuoka Cancer Center Hospital. Among the initially identified candidate somatic single-nucleotide variants (SNVs), 10,279 were validated by manual inspection of the WES data followed by Sanger sequencing. These validated SNVs were used as an objective standard to determine an optimum cutoff value to improve the pipeline. Using this optimized pipeline analysis, 189,381 SNVs were identified in 1,101 samples. The analytical technique presented here is a useful resource for conducting clinical WES, particularly using semiconductor-based sequencing technology.
Identification of causal genomic alterations is a critical step in the implementation of efficacious personalized treatment of patients with cancer. Diverse genomic alterations contribute to tumorigenesis, such as single-base substitutions, small insertions and deletions, chromosomal translocations, recombinational events that create chimeric genes, epigenetic modifications, and transcriptional changes (6, 10, 37) . Nextgeneration sequencing (NGS) is a powerful tool to identify these alterations (13, 25) . Among international collaborative projects, the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have produced more than 15,613 and 11,077 cancer genome, exome, transcriptome, and epigenome sequence datasets, respectively (5, 9, 17, 21) . The Shizuoka Cancer Center's Project HOPE (High-tech Omics-based Patient Evaluation), initiated in January 2014, aims to evaluate patients with cancer by analyzing integrated multiomics data. Project HOPE has analyzed tumor and matched control tissues acquired from 2,145 patients using whole thologist, and samples with tumors weighing >100 mg and those with >50% tumor cells were analyzed. Other restrictions related to histopathological features or cancer types were not imposed, and a blood sample from the same patient was used as a control. Patients granted written informed consent if they anticipated participation in the study. The Institutional Review Board of Shizuoka Cancer Center approved this study. WES was performed using an Ion Proton AmpliSeq Exome Kit (Catalog No. 4487084; Thermo Fisher Scientific, Wilmington, DE, USA). This kit supplies 292,903 amplicons to amplify exons of 18,835 genes. These amplicons cover 57.7 Mb of the human genome, and 34.8 Mb comprises exons of RefSeq genes (28) . Details of the experimental protocol are described by Shimoda et al. (34) . Briefly, DNA was extracted from blood using a QIAmp Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. DNA was extracted from tissue using the same protocol for extracting DNA from blood, except that Proteinase K was added. Exome library preparation was performed using the Ion Torrent AmpliSeq RDY Exome Kit (Thermo Fisher Scientific) following the manufacturer's recommended protocol. Briefly, 10 ng of DNA was used to prepare the template, and the libraries were prepared automatically using the Ion Chef System (Thermo Fisher Scientific). Libraries were quantified using the quantitative polymerase chain reaction, and 7 pM was sequenced using the Ion Torrent Proton Sequencer (Thermo Fisher Scientific) semiconductor DNA sequencer according to the manufacturer's protocol.
Identification of somatic mutations from WES data.
Torrent Suite software (ver. 4.4) was used to convert binary raw data into sequence reads that were mapped to the reference human genome (UCSC hg19). At this step, sequence data derived from tumor and blood samples were analyzed separately. The latter were used as matched controls. Mutations that were identified in tumor samples but not detected in blood were extracted as somatic mutations. For this purpose, we utilized the Ion Reporter AmpliSeq Exome Tumor-Normal workflow template (ver. 4.4) (19) . We added 55,466 mutations compiled from COSMIC (11) and ClinVar (22) to this workflow and used this customization in the following analyses. One variant call format file per analysis was generated by the workflow, which included the identified somatic mutations. This file was further processed using our own scripts to exclude low-confidence and exome sequencing (WES), a panel of cancer-related genes, a panel of chimeric genes, and microarray transcriptome profiling (36, 41) . Robust analytical methods facilitate the identification of genomic changes that predispose to cancer, which are embedded in the vast amount of such sequence data. A data analysis pipeline sequentially applies a suite of programs with adjustable parameters, and different combinations of programs and thresholds may produce diverse results. For example, a recent study showed that one pipeline produces more than 4-fold more single-nucleotide variants (SNVs) from the same dataset than other pipelines (1) . Published studies compared different pipelines that employ open source and commercial software, and most of them analyze NGS data generated by using Illumina's platform (1, 15, 39) . There is no publicly available datasets applicable to WES of clinical samples of cancer tissues collected at single institute, which are sequenced at sufficient depths using the Ion Proton System. The reason for utilizing NGS methods may vary among projects, and the purpose of utilizing an NGSbased approach may affect cutoff values embedded in the pipeline, including the use of databases to exclude germline mutations (3, 20) . Further, distinct error profiles that originate from different sequencing platforms and genomic contexts highlight the importance of platform-and purpose-orientated optimization of the pipeline (4, 14, 29, 43 ). In the current study, we therefore used the Ion Proton System to perform WES of tumor and blood samples derived from 1,058 cancer patients treated at the Shizuoka Cancer Center Hospital. Among the initially identified somatic SNVs, 10,279 were validated using the Integrative Genomics Viewer (IGV) (30) followed by Sanger sequencing. Validated SNVs were used as an objective standard to optimize thresholds for the extraction of somatic mutations. The optimized pipeline significantly reduced false-positive (FP) SNVs while maintaining the same level of true-positive (TP) SNVs. Our results will serve as a useful resource for the analysis of clinical WES data generated using semiconductor-based sequencing technology.
MATERIALS AND METHODS

WES.
To identify somatic genomic alterations in patients with cancer, 1,101 tumor samples were subjected to WES. These samples were acquired from 1,058 cancer patients treated at the Shizuoka Cancer Center Hospital from January 2014 to March 2015. Fresh surgical specimens were diagnosed by a pa-likely FP mutations. Those SNVs with Quality score <30 or depth of coverage <20 were discarded. The effects of mutations were predicted using SnpEff (8) and RefSeq as the source of curated and annotated sequences. Annotation of genes and mutations was performed using the databases as follows: COSMIC (11), ClinVar (22) , dbSNP (33), UniProt (35) and DrugBank (40) . We compiled 665 mutations of genes that encode proteins that serve as targets for therapy identified using several resources (26, 27) . The somatic SNVs that matched this list were annotated as actionable. In the present study, we focused our analyses on SNVs located in an exon or a splice site.
Data analysis workflow.
The workflow is shown in Fig. 1 . Briefly, raw sequence data were processed, trimmed, and aligned to the reference human genome (UCSC hg19). We identified somatic mutations by comparing mutations detected in tumor and blood samples and custom filters to extract the most likely candidates. Subsets of SNVs found in cancer-related genes (2, 7, 12, 16, 18, 20, 23, 24, 37, 38, 42) were randomly selected, and a two-step validation was performed to obtain a set of high-confidence somatic mutations. Optimization of parameters and filtering rules were performed according to the results of the validation.
PRC analysis.
To compare classification performance using various thresholds, precision-recall (PRC) analysis (32) was employed. In the PRC plot, recall = TP / (TP + FN) and precision = TP / (TP + FP) are plotted on the X-and Y-axes, respectively, and FN means false-negative. These metrics capture classification performance better than the specificity and sensitivity values used in standard receiver operating characteristic analysis when applied to imbalanced data (32) . The sum of these values was defined as the score that measured classification performance and was used to define a threshold that maximized this score.
RESULTS AND DISCUSSION
WES analysis of 1,058 patients with cancer WES was performed using 1,101 tumor samples derived from 1,058 patients with cancer. The tissue samples were derived from 49 tissues, and 78% comprised colorectal, lung, stomach, head and neck, breast, and liver tumors (Fig. 2) . This dataset included primary and metastatic cancer tissues of 19 patients. The mean depths of coverage of blood and Fig. 1 Workflow of data analysis. Candidate somatic SNVs were extracted by comparing SNVs in the tumor and matched blood samples. Initial thresholds were configured according to the manufacturer's protocol. IGV and Sanger sequencing were performed using randomly selected candidates to evaluate the efficacy of the initial value. Then thresholds used in filtering step were refined according to the validation results. SNVs in the validated dataset (Fig. 3) . Moreover, the quality score for somatic mutations and the VAF of blood samples were the most effective parameters that distinguished TPs from FPs. Therefore, we employed precision-recall (PRC) analysis. To avoid overfitting, 50% of the SNVs in the validated dataset were randomly extracted and used in the following analyses. Random selection was performed 100 times, and the mean value of the threshold that yielded the maximum score was set as a new criterion. PRC analysis identified quality as more sensitive to classification performance than VAF of blood DNAs (Fig. 4) . A higher quality threshold yielded higher precision at the cost of increasing FNs. Closer inspection of the PRCs curve and scores identified the cutoff criteria that yielded the highest score as follows: Quality ≥60 and VAF (blood) <2%.Therefore, the analysis pipeline was adjusted using these thresholds, except for 665 mutations for which the initial threshold was used to avoid missing actionable genomic mutations.
Landscape of somatic SNVs of 1,058 patients with cancer
Using the optimized threshold, we identified 189,381 somatic SNVs in 1,101 samples ( (Table 3 ). The number of somatic SNVs per sample varied significantly between different tumors and among the same tumor (lowest = 1, highest = 9,121, average = 172), and 500-9121 SNVs were detected in 4.8% of samples (e.g. high mutation load). tumor tissue sequences were 133.8× and 135.2×, respectively, and 90% of the amplicons were covered by ≥20 reads. Initial data analysis identified 213,961 candidate somatic SNVs ( Table 1) .
Validation of candidate somatic SNVs
Two validation datasets were generated from 2 × 10 5 SNVs. The first dataset comprised 275 SNVs, which represented the first 200 patients, which were manually inspected using IGV. The SNVs were classified into categories that represented SNVs that were likely TPs (A), uncertain (B), and likely FPs (C). These SNVs were further subjected to Sanger sequencing. Comparative analysis revealed that 98.8% and 100% of IGV class A and C SNVs, respectively, were validated by Sanger sequencing ( Table 2 ). Note that 34 of 100 class B SNVs were matched to Sanger sequencing result, while the remaining 66 SNVs were not. Closer inspection of class C and B SNVs revealed that two-thirds of these SNVs were located near the end of a read, overlapping a homopolymeric region, and that the mutated sequences were located on only one strand. Therefore, these were classified as class C in the following analyses. In the second dataset, 10,004 other SNVs detected in 1,000 samples were manually evaluated using IGV, according to the criteria stated above. The 10,279 manually inspected SNVs were classified as follows: class A, 8877 (86.4%); class B, 851 (8.3%); and class C, 551 (5.4%). Of the 851 class B SNVs subjected to Sanger sequencing, 485 (45.2%) were confirmed as TPs, and 9,262 (90.1%) of 10,279 SNVs were confirmed as TPs.
Optimization of the data analysis pipeline
Through the validation process, we found that FP SNVs exhibited the characteristics as follows: (1) quality score is 20-30, (2) number of reads with an altered nucleotide was lower compared with those of TPs, and (3) a low (>0) variant allele frequency (VAF) was detected in blood samples. These observations are illustrated by the comparison of the distributions of these parameters between TP and FP GC content, depth, or both in TPs and FPs differed, particularly those with high GC content in the low depth of coverage regions. However, no single cutoff value significantly reduced the number of FPs without excluding TPs. Taken together, these results reveal that IGV analysis excluded 66.7% of class C SNVs by applying a stringent threshold value when focusing on FP reduction. Under these conditions, <1% of TP SNVs were not identified. Therefore, depending on the purpose of the WES analysis, a less stringent threshold might yield data that are more accurate. Moreover, a class B SNV that is difficult to classify as a TP or FP using only IGV requires evaluation using other methods, for example Sanger sequencing, pyrosequencing, or NGS not based on semiconductor sequencing. Further study is required to better characterize the parameters and sequence features that distinguish TPs and FPs in class B SNVs. The WES dataset derived from 1,058 patients with cancer analyzed here shows promise for clinical applications and as a useful resource for WES analysis of cancers,
Effect of pipeline optimization
To further investigate the effect of pipeline optimization, 10,279 validated SNVs were analyzed using the updated thresholds. Reanalysis reduced the number of FP SNVs to 41% (595/1017). In contrast, 99% of TP SNVs (9,168/9,262) were not excluded (Fig. 5A) . When the TP SNVs were stratified according to the IGV results, a similar pattern was observed for classes A and B (Fig. 5B) . Further, there was a significant difference in the reduction of the number of FP SNVs. Specifically, 14.2% of class B FP SNVs (66/466) and 64.6% of the FP SNVs (356/551) were excluded (Fig. 5C) . Thus, even after modification of the pipeline, FPs and FNs were not completely excluded. These erroneous SNVs may be characterized by sequence features or in combination with parameters such as quality, VAF, and depth. Therefore, we analyzed representative sequence features such as GC content, relative ratios of repetitive elements, microsatellites, segmental duplications, and mappability score in the UCSC Genome Browser database (31) . Among them, distribution of particularly using semiconductor-based sequencing technology.
